Figure 1From: Interleukin-6 and rheumatic diseasesSustained ACR20 response to treatment with tocilizumab. ACR, American College of Rheumatology. *P = 0.023, **P = 0.002, §P = 0.008, and †P = 0.043 versus placebo. Reprinted, with permission, from [18]. Copyright © 2002 American College of Rheumatology.Back to article page